Legal & General Group’s Tourmaline Bio TRML Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-11,784
| Closed | -$564K | – | 3438 |
|
|
2025
Q3 | $564K | Buy |
11,784
+3,767
| +47% | +$104K | ﹤0.01% | 2412 |
|
|
2025
Q2 | $128K | Sell |
8,017
-7,426
| -48% | -$120K | ﹤0.01% | 2625 |
|
|
2025
Q1 | $235K | Hold |
15,443
| – | – | ﹤0.01% | 2585 |
|
|
2024
Q4 | $313K | Buy |
15,443
+10,250
| +197% | +$258K | ﹤0.01% | 2599 |
|
|
2024
Q3 | $134K | Sell |
5,193
-14,031
| -73% | -$234K | ﹤0.01% | 2711 |
|
|
2024
Q2 | $247K | Buy |
19,224
+4,211
| +28% | +$67.8K | ﹤0.01% | 2638 |
|
|
2024
Q1 | $344K | Buy |
+15,013
| New | +$529K | ﹤0.01% | 2567 |
|
|
2023
Q2 | – | Sell |
-199
| Closed | -$3.74K | – | 3514 |
|
|
2023
Q1 | $3.74K | Hold |
199
| – | – | ﹤0.01% | 3326 |
|
|
2022
Q4 | $2.03K | Hold |
199
| – | – | ﹤0.01% | 3393 |
|
|
2022
Q3 | $5K | Hold |
199
| – | – | ﹤0.01% | 3410 |
|
|
2022
Q2 | $9K | Sell |
199
-12
| -6% | -$947 | ﹤0.01% | 3385 |
|
|
2022
Q1 | $21K | Buy |
211
+10
| +5% | +$936 | ﹤0.01% | 3233 |
|
|
2021
Q4 | $31K | Buy |
201
+115
| +134% | +$17K | ﹤0.01% | 3143 |
|
|
2021
Q3 | $12K | Hold |
86
| – | – | ﹤0.01% | 3420 |
|
|
2021
Q2 | $13K | Buy |
+86
| New | +$13.2K | ﹤0.01% | 3402 |
|
Legal & General Group's TRML Position: Q4 2025 in Review
Legal & General Group sold out of Tourmaline Bio (TRML) in Q4 2025, closing a stake of 11,784 shares — an estimated $564K sold.
Legal & General Group first reported a position in TRML in Q2 2021 and held it in 15 quarters. The position peaked at $564K in Q3 2025. 0 funds tracked by Wall St. Rank hold TRML as of Q4 2025.
- Legal & General Group reported no remaining Tourmaline Bio position as of Q4 2025 after selling out during the quarter.
- Legal & General Group sold 11,784 Tourmaline Bio shares in Q4 2025, an estimated $564K.
- Legal & General Group first reported a position in Tourmaline Bio in Q2 2021 and held it in 15 quarters.
- Legal & General Group's Tourmaline Bio position peaked at $564K in Q3 2025.
- 0 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2025.
Based on Legal & General Group's 13F filing for Q4 2025, filed 9 Feb 2026.